Generalized Pustular Psoriasis: A Consensus Statement from the National Psoriasis Foundation

By sjmartinez • October 15, 2023

Armstrong AW, Elston CA, Elewski BE, Ferris LK, Gottlieb AB, Lebwohl MG; Medical Board of the National Psoriasis Foundation.. Generalized Pustular Psoriasis: A Consensus Statement from the National Psoriasis Foundation. J Am Acad Dermatol. 2023 Oct 12:S0190-9622(23)02969-9. doi: 10.1016/j.jaad.2023.09.080. Epub ahead of print. PMID: 37838256.

Tags: access, consensus statement, Dermatology, generalized pustular psoriasis, IL-36 inhibition, imsidolimab, national psoriasis foundation, psoriasis, Publications, spesolimab, therapy, Treatment

Treatment of severe perinuclear antineutrophil cytoplasmic antibody-associated vasculitis with efgartigimod

Ghafari-Saravi A, Haussmann A, Wu J, Cheng K. Treatment of severe perinuclear antineutrophil cytoplasmic antibody-associated vasculitis with efgartigimod. JAAD Case Rep. 2024 Mar 15;47:68-71. doi:[...]

Stigmatization and Mental Health Impact of Chronic Pediatric Skin Disorders

Paller AS, Rangel SM, Chamlin SL, Hajek A, Phan S, Hogeling M, Castelo-Soccio L, Lara-Corrales I, Arkin L, Lawley LP, Funk T, Castro Porto Silva[...]

Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60

Egeberg A, Hawkes JE, Somani N, Burge R, See K, Gallo G, McKean-Matthews M, Gooderham M, Han G, Armstrong A. Sustained Improvements in Clinical and[...]